T Cell Receptors Targeting HPV 6 or HPV 11
Summary:
The National Cancer Institute (NCI) seeks research co-development partners and/or licensees for a collection of T cell receptors (TCRs) that specifically target HPV 6 or HPV 11 antigens.
The National Cancer Institute (NCI) seeks research co-development partners and/or licensees for a collection of T cell receptors (TCRs) that specifically target HPV 6 or HPV 11 antigens.
The National Cancer Institute is seeking research co-development partners and licensing collaborators to accelerate the development and commercialization of innovative bifunctional antibody fusion molecules designed to activate and expand engineered TCR-expressing cells, advancing next-generation cancer immunotherapies.
The technology described involves a groundbreaking method for treating intracellular pathogen infections by targeting CD47, a widely expressed transmembrane glycoprotein that acts as a ligand for phagocytic receptors. By administering agents that inhibit CD47 binding to these receptors, the approach enhances the phagocytic removal of infected cells, leading to increased clearance of intracellular pathogens.
The Vaccine Research Center has engineered two monoclonal antibodies, N6 and VRC07-523LS, as new contenders in the fight against HIV-1. These antibodies are designed to target the virus more effectively by removing certain glycans and modifying amino acids to enhance their neutralizing capability and reduce the risk of autoimmunity. The technology holds promise for improved HIV-1 treatments and may offer broader protection due to its potential coverage of various viral variants.
Traf3ip2-/- C57/BL6 mice are a genetically modified mouse model in which the Traf3ip2 gene, responsible for encoding the CIKS adaptor protein essential for IL-17 cytokine signaling, has been disrupted. These mice offer a robust platform for research in autoimmune and inflammatory diseases, as well as potential applications in cancer studies. By eliminating IL-17 signaling and cross-interactions with other pathways, they provide a unique opportunity for drug discovery and proof-of-principle studies, shedding light on disease mechanisms and therapeutic development.
Trispecific and trivalent binding proteins represent a breakthrough in the battle against HIV infection. These specialized proteins are engineered with four polypeptide chains forming three antigen binding sites, enabling precise targeting of HIV target proteins. Addressing the formidable challenges of HIV treatment, including the virus's high mutation rate and the persistence of viral reservoirs, these binding proteins offer a potential solution to breakthrough infections.
Researchers from the National Institute of Allergy and Infectious Diseases (NIAID) and the University of Maryland have unveiled a groundbreaking discovery, revealing the formation of a recombinant heterodimer known as p40-CD5L by combining two known proteins, p40 and CD5L. This heterodimer's significance lies in its ability to stimulate the production of interleukin-4 (IL-4) and interleukin-10 (IL-10) by T cells, which holds great promise for addressing conditions such as allergies, asthma, and tumor immunology.
This technology presents an innovative approach to the treatment of Graft Versus Host Disease (GvHD) by harnessing the therapeutic potential of Pregnancy Specific Glycoproteins (PSG1 and PSG9). The method involves a novel administration technique for these glycoproteins, which had not been previously disclosed prior to the patent application. The technology holds promise in addressing the challenges associated with GvHD treatment, potentially offering new avenues for improving patient outcomes in this complex medical condition.
In this research endeavor, a multifaceted approach has been employed to investigate the intricate roles of CD300 family proteins in immunological processes. Lentiviral transduction of the L929 cell line with mouse and human CD300f genes, followed by puromycin selection, has established cellular models to examine the functions of these receptors. Concurrently, engineered constructs encoding extracellular domains of mouse CD300lb and CD300ld, fused with human IgG1, have been developed for the production of receptor extracellular domain proteins, facilitating studies on protein interactions.
The technology involves the use of specialized cell lines, including HEK 293 cells expressing human CCR1 and CCR2, along with plasmids encoding mouse CCR1 (Ccr1) and CCR2B (Ccr2), as well as their corresponding human receptor sequences. These tools serve as crucial components in the study of chemokine receptors' functions, particularly in the context of inflammatory diseases. By manipulating and analyzing these receptors, researchers can gain insights into their roles in cellular responses related to inflammation.